Faculty

Institution

Unit

Venue

Zahid Hussain Siddik

Professor of Medicine Pharmacology Department of Experimental Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Experimental Therapeutics

Department Of Thoracic-Head And Neck Medical Oncology

Division Of Cancer Medicine

The University of Texas MD Anderson Cancer Center

Zahid Hussain Siddik is currently serving as a Breast Surgical Oncology Professor of Medicine Pharmacology Department of Experimental Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Zahid Hussain Siddik

The University of Texas MD Anderson Cancer Center

Professor of Medicine Pharmacology Department of Experimental Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

pharmacology tumor biology cancer research oncology cancer cells anti-cancer agents therapeutic targets cell biology oncogenes cancer biology biochemistry medicinal chemistry cancer treatment medicine medicinal research molecular cancer pharmacotherapy coordination chemistry transition metal chemistry tumor targeting drug discovery ovarian cancer inorganic chemistry enzyme inhibition gynecologic oncology in vitro toxicology tumor suppressors coordination complex cancer discovery pharmacological research cancer care molecular complexes antitumor activity cancer genetics applied pharmacology cell death oncogenic agent pharmaceutical chemistry hyperthermia inorganic synthesis pharmacokinetics drug targeting structural chemistry cell regulation clinical pharmacology pharmacological studies inhibitory activity apoptosis therapeutic efficacy inorganic compounds colorectal cancer ovarian carcinoma platinum resistance tissue platinum concentration signaling pathways cancer growth chemoprevention strategies organometallic catalysis biological inorganic chemistry thermal therapies hepatobiliary tumors genome instability cisplatin resistance whole body hyperthermia whole-body hyperthermia mutant p53 membrane transport renal function platinum-based antitumor agents confers resistance normal tissue equatorial ligands 1,2-diaminocyclohexane platinum antitumour activity thermal enhancement cytotoxic action

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 398: Novo-111: A Macrocycle Drug Conjugate Engineered for Improved Tumor Targeting and Tolerability.. Cancer Research (2026)

drug deliverytumor biologytumor targetingdrug targetinganti-cancer agentsimproved tumorpharmaceuticsmacrocycle drug conjugateabstract 398pharmacologypolymer-drug conjugatecancer cellsbiomolecular engineering

Microrna-625-3P Increases Chemosensitivity in Ovarian Cancer Cells Through Decreasing Ssx2Ip-Mediated Cisplatin Export in Extracellular Vesicles. Cancers (2026)

oncogenesgynecologic oncologycancer cellstumor biologyextracellular vesiclescell biologyovarian cancer cellsmicrorna detectionmicrorna-625-3p increases chemosensitivitymolecular cell biologyextracellular microvesiclesmolecular biologyovarian cancercancer biology

Abstract 5634: Macrocycle Drug Conjugate Novo-111 Induces Ribosome Biogenesis Stress and is Efficacious in Colorectal Cancer Xenografts. Cancer Research (2025)

colorectal cancercell biologycancer researchpharmacologymolecular biologycancer cells

Editorial Expression of Concern: Upregulation of P27 and Its Inhibition of Cdk2/Cyclin E Activity Following Dna Damage by a Novel Platinum Agent Are Dependent on the Expression of P21. British Journal of Cancer (2025)

oncogenesradiation oncologytumor biologycell deathcell signalingcell biologycancer researchdna damageoncogenic agenttherapeutic targetseditorial expressioncancer cellscell regulationdna repairnovel platinum agent

Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug Oxalitex and Their Significance to Antitumor Response. Molecular Pharmaceutics (2025)

metronomic chemotherapypharmaceuticspharmacologytherapeutic targetspharmacotherapy

Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function.. Journal of Clinical Oncology (2023)

simple formulaprospective evaluationnephrologyapplied pharmacologycarboplatin dosagepharmacokineticspharmacologymedicinedrug metabolismurologypharmacotherapyoncologychronic kidney disease

Development and Validation of a Reversed-Phase Hplc Method for Quantification of 1’-Acetoxychavicol Acetate Content in a Nanostructured Lipid Carrier Formulation. Figshare (2023)

biological engineeringlipidslipid chemistrydrug deliverydrug analysisbiomoleculespharmaceuticsanalytical chemistrychromatographybioanalysischromatographic analysisliquid chromatographylipid analysisreversed-phase hplc methodbiomolecular engineering

Supplementary Data From Oncolytic Hsv Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. (2023)

Bangxing HongValerie ChapaUksha SainiPuneet ModgilDavid E. CohnGuangan HeZahid H. SiddikAnil K. SoodYuanqing YanKaruppaiyah SelvendiranGuangsheng PeiZhongming ZhaoJi Young YooBalveen Kaur

antiviral drug developmentsupplementary dataimmunologyhivdermatologypharmacologyantitumor immunitycisplatin sensitivitycancer immunotherapycancer researchvirologymedicinal researchviral oncologycellular therapyantiviral therapycancer carecancer biologyoncolytic hsv therapyantiviral researchmedical virologycancer genomicsoncology

Supplementary Data From Therapeutic Targeting of Atp7B in Ovarian Carcinoma. (2023)

oncogenesgynecologic oncologycancer cellssupplementary datacell biologymolecular cancergynecologycancer discoverygynecologic cancerstherapeutic targetsovarian cancercancer genomicscancer biology

Alkylating Agents and Platinum Antitumor Compounds. Holland‐Frei Cancer Medicine (2022)

natural product researchpharmaceutical chemistryanti-cancer agentsmedicinal chemistrychemical synthesischemistrypharmacologyplatinum antitumor compounds

1
2
3
4
5
19
10 / page

Zahid Hussain Siddik

Professor of Medicine Pharmacology Department of Experimental Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Surgical Oncology

Division Of Cancer Medicine

Department Of Experimental Therapeutics

Department Of Thoracic-Head And Neck Medical Oncology

Division Of Cancer Medicine

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Zahid Hussain Siddik

The University of Texas MD Anderson Cancer Center

Professor of Medicine Pharmacology Department of Experimental Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 398: Novo-111: A Macrocycle Drug Conjugate Engineered for Improved Tumor Targeting and Tolerability.. Cancer Research (2026)

Microrna-625-3P Increases Chemosensitivity in Ovarian Cancer Cells Through Decreasing Ssx2Ip-Mediated Cisplatin Export in Extracellular Vesicles. Cancers (2026)

Abstract 5634: Macrocycle Drug Conjugate Novo-111 Induces Ribosome Biogenesis Stress and is Efficacious in Colorectal Cancer Xenografts. Cancer Research (2025)

colorectal cancercell biologycancer researchpharmacologymolecular biologycancer cells

Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug Oxalitex and Their Significance to Antitumor Response. Molecular Pharmaceutics (2025)

metronomic chemotherapypharmaceuticspharmacologytherapeutic targetspharmacotherapy

Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function.. Journal of Clinical Oncology (2023)

simple formulaprospective evaluationnephrologyapplied pharmacologycarboplatin dosagepharmacokineticspharmacologymedicinedrug metabolismurologypharmacotherapyoncologychronic kidney disease

Development and Validation of a Reversed-Phase Hplc Method for Quantification of 1’-Acetoxychavicol Acetate Content in a Nanostructured Lipid Carrier Formulation. Figshare (2023)

Supplementary Data From Oncolytic Hsv Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. (2023)

Bangxing HongValerie ChapaUksha SainiPuneet ModgilDavid E. CohnGuangan HeZahid H. SiddikAnil K. SoodYuanqing YanKaruppaiyah SelvendiranGuangsheng PeiZhongming ZhaoJi Young YooBalveen Kaur

Supplementary Data From Therapeutic Targeting of Atp7B in Ovarian Carcinoma. (2023)

oncogenesgynecologic oncologycancer cellssupplementary datacell biologymolecular cancergynecologycancer discoverygynecologic cancerstherapeutic targetsovarian cancercancer genomicscancer biology

Alkylating Agents and Platinum Antitumor Compounds. Holland‐Frei Cancer Medicine (2022)

natural product researchpharmaceutical chemistryanti-cancer agentsmedicinal chemistrychemical synthesischemistrypharmacologyplatinum antitumor compounds

1
2
3
4
5
19
10 / page